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CGRP   calcitonine gene-related peptide 
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nNOS    neuronal nitric oxide synthase 
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Migraine headache is the most common neurological disorder, affecting up to 12% of 
the population. Among others gonadal hormones are important modulators of migraine. After 
puberty women are three to four times more frequently affected by this headache disorder. 
Migraine is commonly known as a throbbing unilateral head pain that is readily 
aggravated by routine physical activities. The clinical definition of migraine includes a host of 
transient neurological symptoms other than pain, namely, nausea, photophobia, phonophobia, 
osmophobia, fatigue, and numerous disturbances in autonomic, mental, sensory and motor 
functions. Numerous factors are putatively involved in the etiology of migraine such as 
susceptibility to particular stimuli (stress, nitrated foods etc) or changes within the central 
nervous system. The neural mechanisms underlying the development of migraine attacks are 
not yet fully understood. 
The throbbing pain experienced in migraine was first attributed to the pulsations of 
abnormally dilated vessels. Nociceptive inputs generated from the pain-sensitive extracerebral 
vessels are then sent via the trigeminal ganglion and subsequently the spinal trigeminal 
nucleus caudalis (TNC) to higher centers involved in pain processing. Nevertheless 
vasodilatation per se could not account for a number of observations in migraine sufferers and 
a neuronal origin of the pain was suggested. According to this hypothesis activation of 
meningeal nociceptors could cause local inflammation, which in turn, further stimulates 
perivascular nociceptive trigeminal fibers. Nitric oxide (NO) may have a crucial role in this 
process as an important mediator in the initiation or the propagation of a neurogenic cranial 
vessel inflammatory response that might eventually result in a migraine attack, and in the 
changes in cerebral blood flow during migraine.  
Another important asset of migraine pathology is the presence of sensitization process 
during the attack. Strassman et al. showed that meningeal primary afferent neurons can 
become mechanically hypersensitive upon exposure of their dural receptive field to 
inflammatory agents. In humans, such mechanical hypersensitivity could mediate the 
throbbing pain of migraine and its worsening during coughing, bending over, or other 
physical activities that increase intracranial pressure.  
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The sensitization process is not only restricted to the peripheral nerves but involves the central 
nervous system. The central sensitization hypothesis, which proposes that altered processing 
of sensory input in the brainstem, principally the trigeminal nucleus caudalis, could account 
for many of the temporal and symptomatic features of migraine. Central sensitization involves 
the TNC, as it is associated with abnormal neuronal excitability in this nucleus. Several 
studies suggest that the NO donor nitroglycerin (NTG) may have a hyperalgesic effect and 
that sensitization of pain pathways in the spinal cord may be caused by – or associated with – 
the generation of NO. High doses of NTG reduced tail flick latency in rats and it seems that 
prolonged elevation of NO in the spinal cord is necessary to maintain central sensitization 
after it has been established. In several models of neuropathic and inflammatory pain, 
neuronal nitric oxid synthase (nNOS) inhibition reduces central sensitization and, indeed, pain 
responses in these models are increased by NO donors. The strongest evidence for the key-
role of NO in the etiology of migraine stems from observations in migraine sufferers and led 
to the NO hypothesis of migraine. Systemic administration of NTG, a NO donor, induces an 
immediate headache in humans. In migraineurs, this headache is more severe, lasts longer, 
and can continue to or be followed by a specific attack of migraine without aura. A biphasic 
headache can also be triggered by NTG in patients suffering from chronic tension-type 
headache. This effect is very likely to be related to NTG-derived NO. The role of NO is also 
supported by the fact that other drugs that are able to induce migraine such histamine, 
reserpine or the serotoninergic antagonist mCPP all have in common to be associated with the 
release of endogenous NO. The infusion of NTG in human induces an immediate throbbing 
headache in healthy subjects, while most migraine patients experience a more severe delayed 
headache, that is identical to spontaneous migraine attacks except the aura. Due to the 
vasodilating effect of NO, the immediate headache is a consequence of the selective action of 
NTG on extra- and intracranial blood vessels, principally the dural arteries and large 
penetrating cerebral arteries, while the delayed headache might be mainly due to an effect of 
NO on neuronal function. Although the half-lives of NTG and NO are very short in vivo, the 
migraine attack occurs several hours after NTG infusion. Thus it appears that NO is a cause of 
migraine through mechanisms that develop over a long period of time. This is consistent with 
the possibility of a delayed and sustained production of NO by nitric oxide synthases (NOSs) 
in a large number of tissues. The importance of endogenous NO production during the 
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headache phase of migraine has been evidenced in the study of Lassen et al. where the 
inhibition of NOS relieved the symptoms of spontaneous migraine with high efficacy.  
Results from animal experiments supports that NTG activates the pain-mediating TNC 
neurons, as the administration of NTG in the rat significantly enhanced the number of Fos-
immunoreactive neurons in brain areas involved in sensory nociceptive perception, including 
the TNC. This effect was maximal after a delay of 4 hours, congruent with the delay of NTG 
induction of migraine in human. Furthermore in the animal model a large number of the 
activated neurons also exhibited NOS immunoreactivity. In neurons of the lower TNC 
(including the upper cervical spinal cord), where most of the trigeminal nociceptors project, 
NTG also increases the expression of nNOS. The most likely explanation for this increased 
nNOS immunoreactivity is the secondary activation of second order nociceptive neurons 
and/or interneurons because of excitation of their peripheral afferents. The increased nNOS 
level in the second order trigeminal neurons can be associated with a central sensitization 
phenomenon, which is characteristic in migraineurs. This effect is inhibited by pretreatment 
with acetyl-salicylate, but not with sumatriptan, indicating that prostanoids are involved in 
this process.  
Ca2+/calmodulin-dependent protein kinase II (CamKII) is a major protein kinase that is 
capable of regulating the activities of many ion channels and receptors. It is found throughout 
the central nervous system and it regulates calcium signalling in synaptic transmission. There 
is strong evidence that CamKII plays a key role in nociceptive processing and sensitization of 
central sensory neurons. In the superficial layers of the spinal dorsal horns it is abundant both 
in neuronal perikarya and in the neuropil. The latter is explained by the fact that more than 
half of dorsal root ganglion cells are CamKII+, especially in the trigeminal ganglion. CamKII 
immunoreactivity in laminae I–II of the spinal cord is increased after subcutaneous injections 
of formalin or capsaicin, or after intrathecal injections of substance P, and this increase can be 
blocked by CamKII inhibitors. After acute noxious stimulation CamKII expression is 
upregulated in dorsal horn synapses formed by peptidergic primary afferents, which are also 
crucial in the pathogenesis of headaches.  
Non-steroidal anti-inflammatory drugs (NSAIDs), such as acetylsalicylic acid 
(Aspirin®), are effective in the treatment of acute migraine headache and tension-type 
headache. This effect could be due to their inhibitory action on cyclooxygenase-2 (COX-2) 
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and prostaglandins in the spinal trigeminal complex, but they could also inhibit NOS 
activation by reducing the induction of transcription factor NF kappa ß. Prostaglandins are 
thought to play role in many neurological functions including the nociceptive processing. 
Several isoforms of their synthetizing enzyme are known: cyclooxygenase-1 (COX-1) and -2 
and the most recently discovered and described cyclooxygenase-3 (COX-3). Recent data 
suggest that COX-2 may play a critical role in brain development and synaptic signaling and 
COX-2 expression is upregulated under several pathological conditions. Mainly COX-2 is 
thought to be responsible for nociceptive processing, but there are also reports suggesting that 
COX-1 may become over-expressed during inflammation. Constitutively expressed COX-2 is 
found in the superficial dorsal horn of the rat spinal cord. It has been proposed that 
prostaglandins synthesized by COX-2 assist in synaptic transmission and enhance 
postsynaptic activity of both excitatory and inhibitory neurotransmitters. In rats, infusion of 
COX-1/COX-2 inhibitors blocked sensitization of meningeal nociceptors and suppressed 
ongoing sensitization in spinal trigeminovascular neurons. A dual-acting COX-2 inhibitor was 
effective in a rat model of capsaicin-induced central sensitization.  
Gonadal steroids, in particular estradiol, modulate nociception and the clinical 
expression of migraine. After puberty women are three times more affected. Abrupt falls in 
estrogen plasma levels can trigger the attacks, e.g. in the premenstrual phase, and they may 
disappear during pregnancy or after menopause, when plasma level of estrogen is stable. In 
the study of Magos et al. a subcutaneous implant of 17β-estradiol decreased headache 
intensity of more than 80% of women with menstrual migraine. Moreover, in women 
undergoing in vitro fertilization, where an analogue of gonadotropin-releasing hormone was 
administered to downregulate estrogen levels, the low levels of 17β-estradiol correlated with 
an increased headache prevalence. The neurobiological mechanisms which underlie these 
modulatory effects of estrogen on migraine remain speculative. Estrogen receptors are present 
on spinal sensory ganglion neurons and in spinal gray matter. In rats, estrogens are reported to 
decrease myogenic tone through a NO-dependent mechanism in rat cerebral arteries. In mice 
it has been shown that estrogens decrease nociception, notably in the trigeminal system. In the 
rat nitroglycerin model estradiol pretreatment blunts calcitonine gene related peptide (CGRP) 
and serotonin (5-HT) changes in the superficial lam
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ovarian hormones, which greatly influence the course of migraine, have indeed the capacity to 
modify the expression of pivotal transmitters in the trigeminovascular nociceptive pathway. 
On the basis of these data we decided to investigate the possible modulatory effects of 
COX-inhibition and hormonal influences in the NTG model of migraine. 
 
 
 II. Aims 
The aims of our studies were to 
i.) study the effect of systemic NTG administration on the CamKII 
expression of the most caudal part of the TNC of the rat 
ii.) examine the possible modulatory effects of estradiol and selective COX 
inhibitors in the above process. 
iii.)  determine which isoform of the COX enzyme plays a role in the nNOS 
activation caused by NTG in the same region.  
 
III. Materials and methods 
All experimental procedures described in this paper followed the guidelines of the 
International Association for the Study of Pain and the European Communities Council 
(86/609/EEC). They were approved by the Ethics Committee of the Faculty of Medicine, 
University of Liège and University of Szeged.  
III.1. CamKII 
III.1.1. Estradiol pretreatment 
Systemic NTG and placebo administration (10 mg/kg s.c.) was performed in male, 
ovariectomised female (ovx) and estradiol treated ovariectomised female (ovx+E) rats. After a 
delay of 4 hours the cervical part of the TNC was removed and we examined the CamKII 
expression in its dorsal horns performing immunohistochemistry. The CamKII expression was 
also quantified with Western blotting. 
III.1.2. Selective COX inhibitor pretreatment 
Thirty minutes before the NTG and placebo treatment (10 mg/kg s.c.), the first group 
of rats were injected subcutaneously with the selective COX-2 inhibitor, NS398 at a dose of 1 
mg/kg, 3 mg/kg or 5 mg/kg. The second group of rats received a s.c. injection of the selective 
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COX-1 inhibitor, SC560 at a dose of 1 mg/kg, 5 mg/kg or 10 mg/kg. The third group of 
animals did not receive any pretreatment. We compared the effect of these drugs on the 
CamKII induction of NTG in the TNC with immunohistochemistry. 
III.2. nNOS 
We also compared the effect of the selective COX-2 inhibitor NS398 (at a dose of 1 
mg/kg, 3 mg/kg or 5 mg/kg) and the selective COX-1 inhibitor SC560 (at a dose of 1 mg/kg, 






IV.1.1. Estradiol pretreatment 
On microscopic examination of immunostained transverse sections, CamKII 
immunoreactivity was found in neurons of the TNC and in the neuropil of lamina II. As 
mentioned in the methods, we focused on immunoreactive neurons. CamKII-Ir cells were 
abundant in the superficial layers of the caudal spinal trigeminal nucleus. The number of cells 
was not significantly different between the various rostro-caudal levels, nor between sides of 
the TNC. After vehicle injection there was no significant difference in the number of CamKII-
Ir cells in the TNC superficial laminae I-III between male rats, ovariectomized (ovx) and 
ovariectomized-estradiol treated females (ovx+E2). In contrast, 4 h after subcutaneous NTG 
administration there was a significant increase in the number of CamKII-Ir cells in males and 
in ovx animals compared with vehicle injections, but no change was found in ovx + E2 rats. 
At the Th1 level the number of CamKII-Ir cells was overall smaller and there was no 
significant difference between animal groups or between treatment conditions. 
The results of Western blotting were in line with those of immunohistochemistry. We 
identified the bands representing the CamKII protein. In male and ovx animals, which had 
received NTG 4 h before, the density of the CamKII protein band in the dorsal portion of the 
C1–C2 segments was increased compared with vehicle-injected rats. In the ovx + E2 group 
the CamKII band was comparable after NTG or vehicle injection. In the Th1 segments there 
was no apparent difference in either of the groups. 
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Densitometric analyses of the blots confirmed that CamKII expression in the dorsal 
C1–C2 segments was significantly enhanced after NTG administration in male and ovx rats, 
but not in ovx + E2 animals and that there was no difference between NTG and vehicle 
injections in the dorsal part of the Th1 spinal segments in either group. 
IV.1.2. Selective COX inhibitor pretreatment 
During microscopic examinations CamKII-Ir cells were numerous in the superficial 
layers of the caudal trigeminal nucleus. NTG produced a significant increase of CamKII-
positive cells in the superficial layers of the caudal trigeminal nucleus in the non-pretreated 
rats (P < 0.05). This phenomenon was similar when rats received the COX-1 inhibitor, SC560 
in various doses (1 mg/kg, 5 mg/kg or 10 mg/kg) before NTG (P < 0.05, P < 0.05, P < 0.05 
respectively). 
Pretreatment with COX-1 inhibitor in any dosages failed to modulate the NTG-
induced CamKII enhancement in the TNC (P = 1 for all doses used).  
At doses of 3 and 5 mg/kg of the selective COX-2 inhibitor NS398, NTG treatment 
failed to induce a statistically significant increase in CamKII expression (P = 0.84, P = 0.7, 
respectively). The NTG-induced CamKII upregulation was attenuated by 3 mg/kg (P < 0.05) 
and 5 mg/kg (P < 0.001) of the selective COX-2 inhibitor. 
IV.2. nNOS 
Transverse sections of the cervical spinal cord demonstrated many nNOS-Ir neurons in 
the superficial laminae of the dorsal horns. These cells are mainly small to medium sized 
neurons (8-15 µm in diameter) with few dentrites. There was no significant difference in the 
number of Ir cells at different levels of the C1-C2 region. NTG produced significant increase 
of nNOS-positive cells in the superficial layers of the caudal trigeminal nucleus in the non-
pretreated rats (P < 0.01).  
This phenomenon was similar when rats received the COX-1 inhibitor, SC560 in 
various doses (1 mg/kg, 5 mg/kg or 10 mg/kg) before NTG (P < 0.05, P < 0.01, P < 0.05 
respectively).  
The COX-2 inhibitor NS398 given at the dose of 3 mg/kg (P = 0.82) or 5 mg/kg (P = 
1), but not of 1 mg/kg (P < 0.05) prior to NTG attenuated the NO-induced nNOS increase. 
Compared to the control group, after NTG injections, the number of nNOS-Ir  neurons was 
significantly lower in the animals, which received the highest dose of NS398 (P < 0.05). 
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V. Discussion 
V.1. NTG-induced CamKII and its modulation by estradiol  
Our data demonstrated that systemic administration of NTG enhances CamKII 
immunoreactivity in laminae I–III of the spinal portion of the TNC. Previous studies have 
demonstrated increases of c-fos and nNOS expression in TNC after NTG administration at a 
dose of 10 mg/kg. The latter may be a molecular basis for a self-amplifying process and 
sensitization, as described clinically during migraine attacks. The effect of the NO donor on 
nNOS expression seemed to be selective for the trigeminal system, as no effect was detected 
in upper thoracic segments. We found the same trigeminal selectivity for the NTG-induced 
CamKII changes. NO probably activates the trigeminal system via an effect on the peripheral 
nociceptive afferents, since capsaicin pretreatment, which destroys these small afferent fibres, 
abolishes the NTG-induced c-fos activation of secondary trigeminal nociceptors. NTG itself 
has different effects on nociception depending on the dose administered. In the rat, an 
intravenous infusion of glycerylnitrate at low doses (2–50 mg/kg per min) does not cause c-
fos activation in the TNC or an increase of jugular vein CGRP levels, despite its capability to 
enhance stimulus sensitivity in the trigeminal system. In humans, microgram doses are used 
intravenously or sublingually to trigger migraine attacks. There may thus be species 
differences in the dose– response relationship of NTG. As far as the time course of the NTG-
induced effects is concerned, its brain concentrations and those of cGMP rise significantly 2 h 
after subcutaneous administration. Fos expression peaks at 1 h in neurons belonging to 
vasoregulatory areas, but only at 4 h in TNC neurons.  
There is strong evidence that CamKII plays a key role in nociceptive processing and 
sensitization of central sensory neurons. It was shown that CamKII located in the 
hippocampus is important regulator during the nociceptive processes induced by formalin, 
glutamate, pro-inflammatory cytokines, and acetic acid injection. Autophosphorylation-
deficient CamKII mutant mice display deficiencies in ongoing nociceptive responses in the 
formalin model, leading to the hypothesis that CamKII is primarily involved in spontaneous 
nociception. CamKII is abundant in the superficial layers of the dorsal horns, where it is 
increased during the noxious stimuli induced by capsaicin or by formalin. Intratechal 
injections of substance P also increases CamKII immunoreactivity in laminae I–II of the 
spinal cord, and this increase can be blocked by CamKII inhibitors. CamKII protein is 
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increased in the medullary dorsal horn following nerve injury to the inferior alveolar nerve 
wherein mechanical allodynia is alleviated by CamKII inhibition. Peripheral CamKII 
immunoreactivity is also increased following complete Freund’s adjuvant -induced 
inflammation. A study provided evidence that capsaicin stimulates autophosphorylation of 
CamKII in sensory neurons and that pharmacological inhibition of CamKII reduces vanilloid 
receptor 1-mediated CGRP release. It was shown that more than half of dorsal root ganglion 
cells are CamKII-positive, especially in the trigeminal ganglion, where it is expressed in 
CGRP- and vanilloid receptor 1-immunoreactive neurons. The hyperexcitability induced by 
capsaicin in trigeminal ganglion neurons via inactivation of I(A) currents is also mediated in 
part by CamKII, as well as the activation of the vanilloid receptor 1 by phosphorylation in rat 
ganglion cells. It has been recently discovered that nociceptive stimuli up-regulate CamKII in 
the dorsal horns by peptidergic afferents, which are also crucial in migraine. In cultured 
neurons it has been shown that CamKII is able to decrease nNOS activity by phosphorylating 
this protein, raising the remote possibility that CamKII might counteract the NTG-induced 
nNOS activation. Moreover, in rats and mice calmodulin can activate various adenylyl 
cyclases which contribute to sensitization in the spinal cord. In a recent study the CamKII 
inhibitor, KN93 dose-dependently prevented the inflammation-induced thermal hyperalgesia 
and mechanical allodynia. We now show that CamKII can also be activated in secondary 
trigeminal nociceptors by high doses of the NO donor NTG, which suggests that it may play a 
role in NTG-induced migraine headaches. Although the involvement of CamKII in 
migraineurs is not yet proven, these data suggest that this enzyme plays an important role in 
migraine pathogenesis. In our study we demonstrated that systemic administration of NTG 
enhances CamKII expression in the superficial layers of the TNC, which suggest that CamKII 
may play a role in sensitization of the trigeminal system and in the pain processes during 
migraine.  
Estrogens are known to modulate nociception, including migraine attacks. It was 
shown that protracted estrogen deprivation tends to have pronociceptive effects in the 
orofacial formalin model of pain in mice and in the rat NTG model, where it blunts CGRP 
and 5-HT changes in the superficial laminae of the TNC. In both instances the observed 
abnormalities are reversed by estradiol administration. In the hippocampus, where CamKII is 
known to be crucial for long-term potentiation, estradiol can rapidly induce its neuronal 
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expression. Our results contrast with the latter, in so far as chronic administration of estradiol 
has no detectable effect on baseline expression of CamKII in TNC, but is able to suppress its 
activation by nitroglycerin. Estrogen receptors are present on spinal sensory ganglion neurons 
and in the spinal grey matter. Estradiol may thus act at the genomic level, which would 
modulate the expression of CamKII and hence annihilate any detectable change in its 
immunoreactivity after NTG administration. Whether these findings are relevant to the 
hormonal influences on migraine remains speculative. However, combined with the clinical 
observation that female migraineurs are more sensitive to certain trigger factors during the 
perimenstrual period, they may suggest that the low estrogen levels of the premenstrual and 
menstrual phases render female migraineurs also more prone to the attack-triggering effects of 
NTG. By the same token, one could draw a parallel between our data in rats, showing that 
chronic estradiol treatment suppresses the selective activation of secondary trigeminal 
nociceptors by nitroglycerin, and the clinical observation that migraine attacks tend to be 
suppressed when sex hormone levels are high and stable, such as during pregnancy.  
In summary, NTG, a NO donor, is able to induce CamKII expression in the superficial 
layers of the TNC in the rat. This effect is annihilated by chronic high concentrations of 
estradiol. Considering the known biological properties of CamKII, one may expect that its 
increased expression after NO enhances nociception in the trigeminal system. In contrast, the 
suppression of this activation by high estradiol levels can be regarded as trigeminal 
antinociception. The acute NTG-induced and the chronic estradiol-dependent changes both 
seem to be selective for the trigeminal sytem. They may thus be relevant to an understanding 
of the delayed NTG-triggered headache attacks in migraineurs and in patients suffering from 
chronic tension-type headache, and of the protective effect of stable plasma estrogen levels. 
They may also give some hints on the molecular effects of NO donors and ovarian steroids in 
trigeminovascular pain syndromes, such as migraine.  
V.2. Effect of COX inhibitors 
The major findings of our studies are (1) the selective COX-2 inhibitor NS398 
attenuated the NTG-induced nNOS and CamKII activation in the superficial layers of the 
most caudal portion of the TNC in the rat, (2) in contrast, the pretreatment with a selective 
COX-1 inhibitor, SC560, failed to modulate this phenomenon.  
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It is not precisely known how NTG administration modifies the nNOS expression in 
the TNC. This modification is probably due to a secondary activation of second order 
nociceptive neurons and/or interneurons by NO excitation of their peripherial afferents, which 
might initiate a self-amplifying process of NO production possibly leading to central 
sensitization. Increased prostaglandin E2 release and NO production of monocytes were 
found in patients with migraine without aura, which indicates that NOS and COX pathways 
are linked in monocytes. In migraine patients, it has been shown that there is an early 
activation of the L-arginine/NO pathway and a late rise in the synthesis of prostanoids after 
the onset of the headache. Since in earlier experiments the nonspecific COX-inhibitor lysine 
acetyl-salicylate treatment attenuated the NTG-induced nNOS expression, the prostanoids 
may have an important role in the signal transduction. Since lysine acetyl-salycilate has COX-
2 inhibiting property, these earlier data are concordant with our present observation about the 
effect of the selective COX-2 inhibitor NS398 on the NTG-induced nNOS activation. Our 
study provides the first evidence that the elevation in nNOS immunoreactivity can be 
influenced selectively by COX inhibitors.  
Furthermore we have shown that the selective COX-2 inhibitor, NS398 attenuated the 
NTG-induced increase of CamKII expression in the superficial layers of the lower TNC in 
rats. In contrast, pre-treatment with a selective COX-1 inhibitor, SC560 was not able to 
modulate this phenomenon. COX-1 can be found in the sensory ganglia and the spinal cord 
and there are results suggesting its involvement in nociception. Previous studies have 
demonstrated that oral SC-560 at a dose of 30 mg/kg can reduce carragenan-induced thermal 
hyperalgesia. It is also known that SC-560 displays low (<15%) bioavailability after given 
orally. Comparable parenteral dosage of SC-560 in our study failed to modulate the NTG 
induced increase of CamKII expression suggesting that COX-1 is not involved in this 
phenomenon.  
It has been shown that systemic NTG increased the expression of COX-2 and 
prostaglandin E2 in the lower brain stem after 4 h. COX-2 inhibitors are effective in the 
treatment of migraine. In animals, constitutively expressed COX-2 is found in the superficial 
dorsal horn of the rat spinal cord. It has been proposed that prostaglandins, synthesized by 
COX-2, assist in synaptic transmission and enhance postsynaptic activity of both excitatory 
and inhibitory neurotransmitters. These data may explain the fact that COX-2- and/or COX-2-
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derived metabolites play an important role in central sensitization and they are thought to 
mediate most of the analgesic effects of NSAIDs. In rats, nimesulide, a preferential COX-2 
inhibitor, showed a significant analgesic effect in tailflick and in formalin tests, and it was 
also effective in these tests after NTG-induced hyperalgesia. Contrary to the COX-2 inhibitor 
celecoxib, the COX-1 inhibitor SC560 failed to reduce edema and hyperalgesia after 
carrageenan induced inflammation in the rat. Oral and intrathecal administration of SC560 did 
not alter the behavior changes in the formalin test where celecoxib and indomethacin were 
effective.  
Taken together these data and our present results suggest that the stimulating effect of 
NTG and that of NO on nNOS and CamKII expression in secondary trigeminal  nociceptors 
are mediated by COX-2-expressing interneurons in the TNC superficial laminae. Therefore, 
COX-2 may participate in the activation of the trigeminal system and may be a crucial 
enzyme in the pathophysiology of headaches. We have demonstrated that NO-induced nNOS 
and CamKII expression in the TNC of the rat is dose-dependently attenuated by pretreatment 
with COX-2 but not with COX-1 inhibitors. These data suggest that prostanoids, especially 
produced via the COX-2 pathway, are involved in NO-mediated activation of the trigeminal 
system. The fact that COX-2 plays a role in this self-amplifying process of the trigeminal area 
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